NUZOLVENCE

Serial Number 98561615
Registration 7783472
700

Registration Progress

Application Filed
May 21, 2024
Under Examination
Approved for Publication
Feb 11, 2025
Published for Opposition
Mar 18, 2025
Registered
May 6, 2025

Basic Information

Serial Number
98561615
Registration Number
7783472
Filing Date
May 21, 2024
Registration Date
May 6, 2025
Published for Opposition
March 18, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
May 6, 2025
Registration
Registered
Classes
005

Rights Holder

Entasis Therapeutics (Ireland) Limited

99
Address
Barrow Street
6th Floor, South Bank House
Dublin 4
IE

Ownership History

Entasis Therapeutics (Ireland) Limited

Original Applicant
99
Dublin 4 IE

Entasis Therapeutics (Ireland) Limited

Original Applicant
99
Dublin 4 IE

Entasis Therapeutics (Ireland) Limited

Owner at Publication
99
Dublin 4 IE

Entasis Therapeutics (Ireland) Limited

Owner at Publication
99
Dublin 4 IE

Entasis Therapeutics (Ireland) Limited

Original Registrant
99
Dublin 4 IE

Entasis Therapeutics (Ireland) Limited

Original Registrant
99
Dublin 4 IE

Legal Representation

Attorney
Steven A. Abreu

Application History

50 events
Date Code Type Description
May 6, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 6, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER
May 6, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 6, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER
Mar 18, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 18, 2025 PUBO A PUBLISHED FOR OPPOSITION
Mar 18, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 18, 2025 PUBO A PUBLISHED FOR OPPOSITION
Mar 12, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 12, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 11, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 11, 2025 PUBO A PUBLISHED FOR OPPOSITION
Feb 11, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 11, 2025 PUBO A PUBLISHED FOR OPPOSITION
Feb 5, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 5, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 16, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 16, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 15, 2025 ALIE A ASSIGNED TO LIE
Jan 15, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 15, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 15, 2025 ALIE A ASSIGNED TO LIE
Jan 15, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 15, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 16, 2024 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 16, 2024 CNSL R SUSPENSION LETTER WRITTEN
Dec 16, 2024 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 16, 2024 GNSL F LETTER OF SUSPENSION E-MAILED
Dec 16, 2024 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 16, 2024 CNSL R SUSPENSION LETTER WRITTEN
Dec 16, 2024 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 16, 2024 GNSL F LETTER OF SUSPENSION E-MAILED
Dec 9, 2024 GNRT F NON-FINAL ACTION E-MAILED
Dec 9, 2024 PC.D I PETITION TO DIRECTOR DISMISSED
Dec 9, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 9, 2024 CNRT R NON-FINAL ACTION WRITTEN
Dec 9, 2024 GNRT F NON-FINAL ACTION E-MAILED
Dec 9, 2024 PC.D I PETITION TO DIRECTOR DISMISSED
Dec 9, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 9, 2024 CNRT R NON-FINAL ACTION WRITTEN
Dec 5, 2024 DOCK D ASSIGNED TO EXAMINER
Dec 5, 2024 DOCK D ASSIGNED TO EXAMINER
Dec 3, 2024 PILM I PETITION INQUIRY LETTER ISSUED
Dec 3, 2024 PILM I PETITION INQUIRY LETTER ISSUED
Dec 2, 2024 APET A ASSIGNED TO PETITION STAFF
Dec 2, 2024 APET A ASSIGNED TO PETITION STAFF
Nov 14, 2024 TPMS I TEAS PETITION TO DIRECTOR-MAKE SPECIAL-RECEIVED
Nov 14, 2024 TPMS I TEAS PETITION TO DIRECTOR-MAKE SPECIAL-RECEIVED
Sep 24, 2024 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED
Sep 24, 2024 TAEA I TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED

Detailed Classifications

Class 005
pharmaceutical preparations, namely, antibiotics; pharmaceutical preparations for the treatment of gonorrhea; pharmaceutical preparations for the treatment of sexually transmitted diseases

Classification

International Classes
005